UPCC 08422 A Phase 1b/2 Open-Label Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody -CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia and Richters Syndrome
Brief description of study
Please refer to Protocol Section 3 (Objectives and Endpoints). Please refer to Protocol Section 3 (Objectives and Endpoints). Please refer to Protocol Section 3 (Objectives and Endpoints).
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Medical Research
-
Age: - 99 Years
-
Gender: All
Updated on
14 Jun 2023.
Study ID: 851383
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
